ADC Therapeutics SA EPS - Earnings per Share 2019-2022 | ADCT

ADC Therapeutics SA eps - earnings per share from 2019 to 2022. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
ADC Therapeutics SA Annual EPS
2021 $-3.00
2020 $-3.77
2019 $-2.36
2018 $-2.64
ADC Therapeutics SA Quarterly EPS
2022-03-31 $-0.22
2021-12-31 $-0.45
2021-09-30 $-0.93
2021-06-30 $-0.95
2021-03-31 $-0.67
2020-12-31 $-0.62
2020-09-30 $-0.29
2020-06-30 $-2.01
2020-03-31 $-0.85
2019-12-31 $0.00
2019-09-30 $-0.62
2019-06-30 $-0.49
2018-12-31 $0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.500B $0.034B
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $165.194B 10.05
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.361B 16.35
Biohaven Pharmaceutical Holding (BHVN) United States $10.098B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.208B 0.00
Emergent Biosolutions (EBS) United States $1.617B 6.92
Arcus Biosciences (RCUS) United States $1.305B 33.09
Myovant Sciences (MYOV) United Kingdom $0.956B 0.00
Zymeworks (ZYME) Canada $0.368B 0.00
Gelesis Holdings (GLS) United States $0.349B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.108B 22.10
SQZ Biotechnologies (SQZ) United States $0.097B 0.00